Efficacy of anti-inflammatory therapy in a model of acute seizures and in a population of pediatric drug resistant epileptics
Nicola Marchi, Tiziana Granata, Elena Freri, Emilio Ciusani, Francesca Ragona, Vikram Puvenna, Quingshan Teng, Andreas Alexopolous, Damir Janigro, Nicola Marchi, Tiziana Granata, Elena Freri, Emilio Ciusani, Francesca Ragona, Vikram Puvenna, Quingshan Teng, Andreas Alexopolous, Damir Janigro
Abstract
Targeting pro-inflammatory events to reduce seizures is gaining momentum. Experimentally, antagonism of inflammatory processes and of blood-brain barrier (BBB) damage has been demonstrated to be beneficial in reducing status epilepticus (SE). Clinically, a role of inflammation in the pathophysiology of drug resistant epilepsies is suspected. However, the use anti-inflammatory drug such as glucocorticosteroids (GCs) is limited to selected pediatric epileptic syndromes and spasms. Lack of animal data may be one of the reasons for the limited use of GCs in epilepsy. We evaluated the effect of the CG dexamethasone in reducing the onset and the severity of pilocarpine SE in rats. We assessed BBB integrity by measuring serum S100β and Evans Blue brain extravasation. Electrophysiological monitoring and hematologic measurements (WBCs and IL-1β) were performed. We reviewed the effect of add on dexamethasone treatment on a population of pediatric patients affected by drug resistant epilepsy. We excluded subjects affected by West, Landau-Kleffner or Lennox-Gastaut syndromes and Rasmussen encephalitis, known to respond to GCs or adrenocorticotropic hormone (ACTH). The effect of two additional GCs, methylprednisolone and hydrocortisone, was also reviewed in this population. When dexamethasone treatment preceded exposure to the convulsive agent pilocarpine, the number of rats developing status epilepticus (SE) was reduced. When SE developed, the time-to-onset was significantly delayed compared to pilocarpine alone and mortality associated with pilocarpine-SE was abolished. Dexamethasone significantly protected the BBB from damage. The clinical study included pediatric drug resistant epileptic subjects receiving add on GC treatments. Decreased seizure frequency (≥ 50%) or interruption of status epilepticus was observed in the majority of the subjects, regardless of the underlying pathology. Our experimental results point to a seizure-reducing effect of dexamethasone. The mechanism encompasses improvement of BBB integrity. Our results also suggest that add on GCs could be of efficacy in controlling pediatric drug resistant seizures.
Conflict of interest statement
Competing Interests: The authors have read the journal's policy and have the following conflicts: Drs. Janigro and Marchi have a U.S. Patent on serum markers of BBB function. This does not alter the authors' adherence to all the PLoS ONE policies on sharing data and materials.
Figures
References
- Kwan P, Arzimanoglou A, Berg AT, Brodie MJ, Allen HW, et al. Definition of drug resistant epilepsy: Consensus proposal by the ad hoc Task Force of the ILAE Commission on Therapeutic Strategies. Epilepsia 2009
- Elkassabany NM, Bhatia J, Deogaonkar A, Barnett GH, Lotto M, et al. Perioperative complications of blood brain barrier disruption under general anesthesia: a retrospective review. J Neurosurg Anesthesiol. 2008;20:45–48.
- Korn A, Golan H, Melamed I, Pascual-Marqui R, Friedman A. Focal cortical dysfunction and blood-brain barrier disruption in patients with Postconcussion syndrome. J Clin Neurophysiol. 2005;22:1–9.
- Marchi N, Angelov L, Masaryk T, Fazio V, Granata T, et al. Seizure-promoting effect of blood-brain barrier disruption. Epilepsia. 2007;48:732–742.
- Ivens S, Kaufer D, Flores LP, Bechmann I, Zumsteg D, et al. TGF-beta receptor-mediated albumin uptake into astrocytes is involved in neocortical epileptogenesis. Brain. 2007;130:535–547.
- Seiffert E, Dreier JP, Ivens S, Bechmann I, Tomkins O, et al. Lasting blood-brain barrier disruption induces epileptic focus in the rat somatosensory cortex. J Neurosci. 2004;24:7829–7836.
- Tomkins O, Friedman O, Ivens S, Reiffurth C, Major S, et al. Blood-brain barrier disruption results in delayed functional and structural alterations in the rat neocortex. Neurobiol Dis. 2007;25:367–377.
- Oby E, Janigro D. The blood-brain barrier and epilepsy. Epilepsia. 2006;47:1761–1774.
- Cornford EM. Epilepsy and the blood brain barrier: endothelial cell responses to seizures. Adv Neurol. 1999;79:845–862.
- Cornford EM, Nguyen EV, Landaw EM. Acute upregulation of blood-brain barrier glucose transporter activity in seizures. Am J Physiol Heart Circ Physiol. 2000;279:H1346–H1354.
- van Vliet EA, da Costa AS, Redeker S, van Schaik R, Aronica E, et al. Blood-brain barrier leakage may lead to progression of temporal lobe epilepsy. Brain. 2007;130:521–534.
- Amato C, Elia M, Musumeci SA, Bisceglie P, Moschini M. Transient MRI abnormalities associated with partial status epilepticus: a case report. Eur J Radiol. 2001;38:50–54.
- Huang CC, Wai YY, Chu NS, Liou CW, Pang CY, et al. Mitochondrial encephalomyopathies: CT and MRI findings and correlations with clinical features. Eur Neurol. 1995;35:199–205.
- Lansberg MG, O'Brien MW, Norbash AM, Moseley ME, Morrell M, et al. MRI abnormalities associated with partial status epilepticus. Neurology. 1999;52:1021–1027.
- Paladin F, Capovilla G, Bonazza A, Mameli R. Utility of Tc 99 m HMPAO SPECT in the early diagnosis of Rasmussen's syndrome. Ital J Neurol Sci. 1998;19:217–220.
- Paladin F, Bonazza A, Mameli R, Mainardi F. Cryptogenic temporal lobe epilepsy. semi-quantitative interictal 99 mTc HMPAO SPECT: statistical correlation with clinical data and EEG. Ital J Neurol Sci. 1999;20:237–242.
- Tan KM, Britton JW, Buchhalter JR, Worrell GA, Lagerlund TD, et al. Influence of subtraction ictal SPECT on surgical management in focal epilepsy of indeterminate localization: a prospective study. Epilepsy Res. 2008;82:190–193.
- Alvarez V, Maeder P, Rossetti AO. Postictal blood-brain barrier breakdown on contrast-enhanced MRI. Epilepsy Behav. 2010;17:302–303.
- Siemes H, Siegert M, Aksu F, Emrich R, Hanefeld F, et al. CSF protein profile in infantile spasms. Influence of etiology and ACTH or dexamethasone treatment. Epilepsia. 1984;25:368–376.
- Grosso S, Farnetani M, Mostardini R, Cordelli D, Berardi R, et al. A comparative study of hydrocortisone versus deflazacort in drug-resistant epilepsy of childhood. Epilepsy Res. 2008;81:80–85.
- Sevilla-Castillo RA, Palacios GC, Ramirez-Campos J, Mora-Puga M, Diaz-Bustos R. Methylprednisolone for the treatment of children with refractory epilepsy. Neuropediatrics. 2009;40:265–268.
- Verhelst H, Boon P, Buyse G, Ceulemans B, D'Hooghe M, et al. Steroids in intractable childhood epilepsy: clinical experience and review of the literature. Seizure. 2005;14:412–421.
- Snead OC, III, Benton JW, Myers GJ. ACTH and prednisone in childhood seizure disorders. Neurology. 1983;33:966–970.
- Uva L, Librizzi L, Marchi N, Noe F, Bongiovanni R, et al. Acute induction of epileptiform discharges by pilocarpine in the in vitro isolated guinea-pig brain requires enhancement of blood-brain barrier permeability. Neuroscience. 2008;151:303–312.
- Vezzani A, Granata T. Brain inflammation in epilepsy: experimental and clinical evidence. Epilepsia. 2005;46:1724–1743.
- Marchi N, Oby E, Batra A, Uva L, de Curtis M, et al. In vivo and in vitro effects of pilocarpine: relevance to ictogenesis. Epilepsia. 2007;48:1934–1946.
- Carmen J, Okafor K, Ike E. The effects of lithium therapy on leukocytes: a 1-year follow-up study. J Natl Med Assoc. 1993;85:301–303.
- Fabene PF, Navarro MG, Martinello M, Rossi B, Merigo F, et al. A role for leukocyte-endothelial adhesion mechanisms in epilepsy. Nat Med. 2008;14:1377–1383.
- Marchi N, Fan Q, Ghosh C, Fazio V, Bertolini F, et al. Antagonism of peripheral inflammation reduces the severity of status epilepticus. Neurobiol Dis. 2009;33:171–181.
- Sinclair DB. Prednisone therapy in pediatric epilepsy. Pediatr Neurol. 2003;28:194–198.
- Marchi N, Teng Q, Ghosh C, Fan Q, Nguyen MT, et al. Blood-brain barrier damage, but not parenchymal white blood cells, is a hallmark of seizure activity. Brain Res 2010
- Kanner AA, Marchi N, Fazio V, Mayberg MR, Koltz MT, et al. Serum S100beta: a noninvasive marker of blood-brain barrier function and brain lesions. Cancer. 2003;97:2806–2813.
- Hermsen CC, Mommers E, van de WT, Sauerwein RW, Eling WM. Convulsions due to increased permeability of the blood-brain barrier in experimental cerebral malaria can be prevented by splenectomy or anti-T cell treatment. J Infect Dis. 1998;178:1225–1227.
- Razani-Boroujerdi S, Behl M, Hahn FF, Pena-Philippides JC, Hutt J, et al. Role of muscarinic receptors in the regulation of immune and inflammatory responses. J Neuroimmunol. 2008;194:83–88.
- Ivens S, Gabriel S, Greenberg G, Friedman A, Shelef I. Blood-brain barrier breakdown as a novel mechanism underlying cerebral hyperperfusion syndrome. J Neurol. 2010;257:615–620.
- Stefan H, Lopes da Silva FH, Loscher W, Schmidt D, Perucca E, et al. Epileptogenesis and rational therapeutic strategies. Acta Neurol Scand. 2006;113:139–155.
- Granata T. Rasmussen's syndrome. Neurol Sci. 2003;24(Suppl 4):S239–S243.
- Granata T, Gobbi G, Spreafico R, Vigevano F, Capovilla G, et al. Rasmussen's encephalitis: early characteristics allow diagnosis. Neurology. 2003;60:422–425.
- Araki T, Otsubo H, Makino Y, Elliott I, Iida K, et al. Efficacy of dexamathasone on cerebral swelling and seizures during subdural grid EEG recording in children. Epilepsia. 2006;47:176–180.
- Ravizza T, Gagliardi B, Noe F, Boer K, Aronica E, et al. Innate and adaptive immunity during epileptogenesis and spontaneous seizures: evidence from experimental models and human temporal lobe epilepsy. Neurobiol Dis. 2008;29:142–160.
- Vezzani A, Balosso S, Maroso M, Zardoni D, Noe F, et al. ICE/caspase 1 inhibitors and IL-1beta receptor antagonists as potential therapeutics in epilepsy. Curr Opin Investig Drugs. 2010;11:43–50.
- Leite JP, Cavalheiro EA. Effects of conventional antiepileptic drugs in a model of spontaneous recurrent seizures in rats. Epilepsy Res. 1995;20:93–104.
- Leite JP, Garcia-Cairasco N, Cavalheiro EA. New insights from the use of pilocarpine and kainate models. Epilepsy Res. 2002;50:93–103.
- Betz AL, Coester HC. Effect of steroids on edema and sodium uptake of the brain during focal ischemia in rats. Stroke. 1990;21:1199–1204.
- Cucullo L, Hallene K, Dini G, Dal Toso R, Janigro D. Glycerophosphoinositol and dexamethasone improve transendothelial electrical resistance in an in vitro study of the blood-brain barrier. Brain Res. 2004;997:147–151.
- Gutin PH. Corticosteroid therapy in patients with cerebral tumors: benefits, mechanisms, problems, practicalities. Semin Oncol. 1975;2:49–56.
- Rook GA. Glucocorticoids and immune function. Baillieres Best Pract Res Clin Endocrinol Metab. 1999;13:567–581.
- Riazi K, Galic MA, Pittman QJ. Contributions of peripheral inflammation to seizure susceptibility: cytokines and brain excitability. Epilepsy Res. 2010;89:34–42.
- Maroso M, Balosso S, Ravizza T, Liu J, Aronica E, et al. Toll-like receptor 4 and high-mobility group box-1 are involved in ictogenesis and can be targeted to reduce seizures. Nat Med. 2010;16:413–419.
- Blair RE, Deshpande LS, Holbert WH, Churn SB, DeLorenzo RJ. Age-dependent mortality in the pilocarpine model of status epilepticus. Neurosci Lett. 2009;453:233–237.
- Rogawski MA, Reddy DS. Neurosteroids and infantile spasms: the deoxycorticosterone hypothesis. Int Rev Neurobiol. 2002;49:199–219.
Source: PubMed